BTBP(600161) 国海证券·2024-10-29 06:12Investment Rating - The report assigns a "Buy" rating for the company, Tian Tan Biological Products [2][4]. Core Insights - The company reported a revenue of 4.073 billion yuan for the first three quarters of 2024, representing a year-over-year increase of 1.28%. The net profit attributable to the parent company was 1.052 billion yuan, up 18.52% year-over-year [2][3]. - In Q3 2024, the company experienced a revenue decline of 7.44% year-over-year, totaling 1.232 billion yuan, while the net profit attributable to the parent company was 326 million yuan, reflecting a year-over-year increase of 1.57% [3]. - The company has successfully acquired Wuhan Zhongyuan Ruide for a total consideration of 185 million USD, which will enhance its blood product resources and overall competitiveness in the industry [4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a gross margin of 54.54%, an increase of 2.76 percentage points year-over-year. The net profit margin improved by 3.31 percentage points to 35.87% [3]. - The report forecasts revenues of 5.452 billion yuan, 6.421 billion yuan, and 7.587 billion yuan for 2024, 2025, and 2026 respectively, with corresponding net profits of 1.359 billion yuan, 1.629 billion yuan, and 1.989 billion yuan [4][7]. - The projected P/E ratios for 2024, 2025, and 2026 are 32.45X, 27.06X, and 22.17X respectively, indicating a favorable valuation trend [4][7].